Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LOL-King's English is what they want LG not pidgin' . Haha
ljk- Sorry about your experience. Light shining works for me. I hope you will send the offensive material to Matt. Cheers.
There may be fewer of them when dip buys get cancelled. I did not think the RUT max pain of 500 was doable but we are not that far away now.
Concur- learning to trade is an education and will cost just as much. Paying attention to the Hed will give anyone advanced credentials in a methodology with good results. Lots of good traders here with lots of approaches to the market.
ES opened 1086.25
NQ 1451
RUT 559.60
Could be fun.
Anybody gonna short gold?
SM- should be running 6.181, 5.83 was replaced by this new version. Happened about a month ago. Gotta get the new version and install it to get updates now.
All I know I got from Bruce's link to Trend Micro, it is a full page of links and details about the worm. Cheers (Plugger aka we don' need no stinking MSFT upgrade) <g>
Hi Bruce, I went to the link in your post and the worm is described as an NT W2000 XP exploiter, and the descriptions are all about those versions vulneribilities. I also run, Ad-Aware, Spybot, etc. Just rechecked Spybot and it has the Wurld description so, I figure my late adoption of anything makes me as safe as possible. I have not pressed my luck to go to Larry's site. <g> Thx again.
Thanks for the headsup! I am safe since I refuse to upgrade to MSFT's latest vulneribility level. I wonder if Larry is running a Linux machine or if he is as cheap as me and is running W98SE. <g>
Nooooooooooo! Aaaargh! Where is the link, I need confirmation!
Might want to check here. All you ever wanted to know about CCI and then some.
http://www.woodiescciclub.com/
SSF= Single Stock Futures I like using them like options. Thin volume can mean big swings but for swings they work well.Watch the spreads.
Edit: Check here
http://www.onechicago.com/030000_products/oc_030000.html
http://www.nqlx.com/products/basic.asp
OT Sorry about Wonderdog. Derek sends his best. As to the Rx disparity. My vet in England went on an extended tour of the Middle East, he took handfuls of Cipro, Ampecillin(sic), etc. from the vet supplies. I guess he didn't think there was a lot of difference.
But have they seen either of the Yankee Tshirts you have to wear?
Zeev and Plugger not, I repeat , not going toe to toe. I admired his sentence and said so, mayhap too elliptically. It was a beautiful thing. ( Wonder may have been better as wondering but that is a quibble and open to debate.)
"We can't spend a lot of time probing these old wounds with scraggy fingers and wonder with almost a prurient bent as to who did what to whom."
Hey! I thought your first language was Hungarian? Stop embarassing the English as first language speakers! LOL
Great idea! Thanks for the board.
4 I liked mine but this one better, and you can sing to the tune of Midnite Train to Georgia .
Zee'xit?
Great! Now my spelling is being corrected after I have been wakened from a sound sleep! Hrumph.
P.S. Gaby Hayes is the correct spelling. LOL
Hey! It wasn't my eyes that read the chart , nor my finger on the sell button. Ya don't think the Curse carries over to trading do ya? LOL
You woke me up,now go to your room!
Dagnabit!! Would you please be quiet! People are trying to sleep! Sheesh! LOL
"Estimates of post-Thanksgiving retail sales ranged yesterday from flat to modest, leaving many merchants hoping that things would pick up later in the season.
Scott Krugman, a spokesman for the National Retail Federation, said this year's weekend after Thanksgiving was "on a par with last year -- it was no worse than last year." He said he expected "exponential improvement" in sales before Christmas, an increase that would result in the federation's forecast of 5.7 percent higher holiday sales this year.
Marshal Cohen, senior analyst for the NPD Group, a market research firm, more generously estimated the sales total for Friday and the weekend at 3 to 4 percent higher than last year's, but that rate of growth was still far below one widely quoted estimate for last year's three-day shopping weekend of more than 12 percent growth over 2001.
"Consumers are telling me they don't have money in their pockets," Mr. Cohen said. "The economy is recovering, but they don't see it yet."
Yet some retailers, especially discounters, reported big crowds, especially for early-bird specials for featured items, like $29 DVD players and bargain toys. Wal-Mart announced sales of $1.52 billion on Friday, a 6.3 percent increase over last year -- and a single-day company sales record. But the increase was down from its 2002 gain of 14.5 percent over Black Friday the year before.
At J. C. Penney, results were "strong, and foot traffic was definitely better than last year," said Vanessa Castagna, chairman and chief executive of the Penney stores. Catalog and Internet sales, home furnishings and gifts were particularly strong, she said, as was jewelry. "People are buying diamonds," she said.
Bucking the less promotional atmosphere among many retailers, Penney is being aggressive, and early-bird specials, which Ms. Castagna called "door-busters," brought more shoppers into the store than last year, she said. ..."
NY Times Dec 1
Zeev- Abelson agrees about value. Fm. this week's Barron's
"POOR MERCK. UNLIKE THE OTHER drug makers, it didn't get to celebrate passage of Medicare's new prescription-drug feature that could mean a lot more dough in the companies' coffers. Or, at least, its stock didn't get to participate in the little party investors threw for the group when Congress voted yea before scrambling for the exit.
Since none of the senators or representatives who gave the bill a thumbs-up or thumbs-down actually read it before doing so and hence were a bit cloudy on what it really contained, to say nothing of what effect it might have, their comments were more than usually uninformative. Nonetheless, since the pharmaceutical industry, which has many virtues but altruism is not salient among them, was one of the unacknowledged architects of the new law, we feel safe in hazarding the measure will do it no harm.
But investors are sour on Merck, so last week, it had to stand out in the cold, its face pressed to the window, enviously watching the other drug stocks whoop it up. As if things weren't bad enough, The Wall Street Journal on Friday ran a front-page feature on the company, which was one long tale of woe. And undeniably, Merck has had some punk luck lately: Two of its presumed promising drugs in late-stage development -- one for treating diabetes and the other for depression -- were withdrawn in just a matter of weeks.
What we learned from the Journal story was that the Street's knock on Merck, punk luck aside, is that the company retains a heavy commitment to research, has implicit trust in its scientists, shuns gussying up old drugs in new guises and isn't eager to merge with Schering-Plough. All of which we perversely find quite admirable.
It's a rare drug company that doesn't hit a rough patch and incur Wall Street's displeasure. But, after perusing the Journal story, which, incidentally, was a neat job of describing why everyone's so down on Merck, and leafing through analysts' reports (most of them less than enthusiastic), the company's third-quarter report and the transcript of the conference call that followed its release, we think Merck's a buy.
The stock's selling at 40 and change, just about its lowest price in six years and its meagerest multiple in eight. It's also at less than half the highs reached a scant few years ago, when it traded in the mid-90s. Yet, even though you'd never know it listening to the growling and howling from the peanut gallery, the company's not going out of business, its balance sheet is healthy, it's still earning money and quite a bit of it, and its pipeline of drugs, believe it or not, is not empty.
The estimates for this year run $2.90-$2.95 and maybe $3, a bit more, for next. That gives Merck a P/E of around 13, the lowest among the top dozen drug producers, most of which sport multiples at least twice as large. Without blinking recent research stumbles or the fact that one of its major formulations is slated to come off patent in 2006, the company boasts some likely-looking products on tap, notably a cervical cancer vaccine now in Phase III trials that Tim Anderson, Prudential's analyst, says could be a $3 billion number and hit the market sooner than expected.
In any case, whatever happened to the notion of buying stocks when they're down? That went out of fashion, we supposed, about the same time the idea of investigating before you invest did."
You may like this. S2 worked today
http://www.hardrightedge.com/tradewinds.htm
We can schedule a session on pre-mature exit.
Plugger also covered since he is a huge chicken.
It got there because I told you to put it there! Sheesh, the memories of some people.
TC- He uses Qcharts. He is challenged in the area of technology and abbreviations.
Michael Jordan is gonna drive a Bronco?? Last time I saw him he was driving a BMW convertible.
Globex traders- Margin reqs. have been raised. Make sure your trading accounts are up to scratch.
Mon Nov 17 04:30:16 2003 EST Effective November 16 2003, CME has updated their margin requirements.
Many products, in particular equity index related products, have notably higher margin requirements, as much as 15%.
Traders are advised to examine their IB margin requirements and ensure their accounts are within limits as soon as possible.
Full details are available in a download in the CME Performance Bond Advisory at http://www.
cme.
com/files/pbadv0396.
pdf.
09:15 ET Industrial Production 0.2% vs 0.4% consensus; Capacity Utilization 75.0% vs 75.0% consensus :
08:30 ET PPI 0.8% vs 0.2% consensus; core PPI 0.5% vs 0.1% consensus :
08:30 ET Retail Sales -0.3% vs -0.2% consensus; ex-auto 0.2% vs 0.2% consensus :
08:35 ET S&P futures vs fair value: -0.6. Nasdaq futures vs fair value: -3.0. Futures trade dips a bit on the rise in October PPI and the decline in October retail sales... The PPI checked in at 0.8% (consensus of 0.2%), while retail sales came in at -0.3% (consensus of -0.2%)... However, retail sales, excluding autos, matched the consensus expectation of 0.2%... Nonetheless, the cash market looks set for a slightly lower open with limited catalysts to the upside to move it higher from its (nearly) 52-week highs
Hibernating?
07:07 ET WMT sees Q4 of $0.63-0.65; consensus $0.65
So, with this estimate we should see 4% rise? LOL
Juice- you know you get in trouble when you think! Caboose, caboose, caboose. LOL
07:45 ET New safety rules on trucking will likely increase costs -- WSJ : The Wall Street Journal reports trucking rates are expected to increase along with major changes to truck-driver hours. The article notes the new rules increase the time that truck drivers must set aside to rest in each 24-hour period to 10 hours from eight hours, and the total time a driver can be on duty will fall to 14 hours from 15 hours. The government estimates the new rules could cost trucking companies about $1.3 billion a year. Wal-Mart Stores, which unsuccessfully opposed the new rules, believes the more stringent 14-hour rule will reduce its drivers' daily work time by 6% on average and cause it to add 275 new drivers and 300 new trucks to handle the same amount of cargo. The retailer expects the changes to cost it $24 million just for the additional trucks
07:37 ET MRK upgraded at Prudential 43.87: -- Update -- Prudential upgrades to Overweight from Underweight and maintains their $54 target; co's pipeline contains no fewer than 5 drugs in Phase III with significant sales potential: Zocor/Zetia for cholesterol reduction (launch mid-04), Arcoxia as a replacement for Vioxx pain drug (possibly late 2004), substance P for depression (2005), cervical cancer vaccine (2006), and dual PPAR diabetes drug (2006); in addition, MRK is a play on AZN's hot new pipeline drug Exanta (could launch 2H04), as MRK gets almost 20% royalty; finally, firm says that MRK appears to be a vastly "under-owned" name, near-term earnings uncertainty and the 2006 US Zocor patent expiry are factored into its steeply-discounted valuation, and the stock's dividend yield of almost 3.5% is second highest in the group. [Briefing note: MRK announced this morning that it has discontinued Phase III trials for substance P... see 7:11 comment.]